The primary outcome was the response to treatment, defined by decrease of inflammatory ocular signs.

Four ( 50% ) patients were of female gender and the median ( IQR ) age was 41 years. The median number of previous immunosupressants was of 5.5.
Seven patients had been previously treated with anti-TNF-alpha [ Infliximab ( n=5 ) and Adalimumab ( n=2 ) ].
The immunosupressive drugs used in association with Tocilizumab were Azathioprine ( n=2 ), Mycophenolate mofetil ( n=2 ) and Methotrexate ( n=2 ).

After a median follow-up of 8 months, 6/8 ( 75% ) improved under Tocilizumab and 2 ( 25% ) were non-responders. The visual acuity improved in five patients.

The median dose of Prednisolone decreased from 16mg/day to 10 mg/day, at baseline and at the end of follow-up, respectively.